EverPoint Asset Management’s TherapeuticsMD TXMD Stock Holding History

EverPoint Asset Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$692K	Buy	+2,400	New	+$744K	0.01%	384

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EverPoint Asset Management's TXMD Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in TherapeuticsMD (TXMD) in Q4 2016: 2,400 shares worth $692K. The stake represents 0.01% of the portfolio and ranks #384 among its holdings.

146 funds tracked by Wall St. Rank hold TXMD as of Q4 2016.

EverPoint Asset Management held 2,400 shares of TherapeuticsMD worth $692K as of Q4 2016.
TherapeuticsMD was a new EverPoint Asset Management position in Q4 2016.
TherapeuticsMD made up 0.01% of EverPoint Asset Management's portfolio in Q4 2016, its #384 holding.
146 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.